Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erdafitinib vs Intravesical Chemotherapy in High-Risk NMIBC with FGFR Alterations
2023-510306-40-00Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of erdafitinib in bladder cancer (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Recurrence-free survival. Started May 2024; status: completed.
02
Drugs
erdafitinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2023-510306-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510306-40-00.